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Cisplatin is one of the most widely used chemotherap utic anti-cancer drugs due 
to its ability to effectively damage DNA and cause cell death. Despite this, cisplatin still 
suffers from two main drawbacks: toxicity and drug resistance. Many cisplatin-like 
compounds have been synthesized via traditional methods of drug design but very few 
have been able to enter clinical trials or even be approved for clinical use. The reason 
why so many compounds have been rejected is that their reaction mechanisms are rarely 
understood. By observing and studying the reaction mechanisms of a drug at the 
molecular level, the reaction can be optimized to enhance its therapeutic effects. The 
powerful technique of time-resolved pump-probe femtosecond laser spectroscopy was 
performed by Lu et al. to reveal the extremely high reactivity of cisplatin with weakly-
bound electrons, thus providing a deeper understanding of this drug’s therapeutic effects. 
Taking advantage of this reaction mechanism, a molecular promoter can be identified to 
amplify the therapeutic efficacy of cisplatin by combination in a synergistic manner. 
Through cell survival rate measurements, fluorescence microscopic studies to view cell 
death, cell cycle analysis and DNA fragmentation measurements via flow cytometry, as 
well as absorption spectroscopic studies, the synergistic effects between cisplatin and a 
new molecular promoter (PM2A) were measured. This new chemotherapeutic regimen, 
which was designed based on the electron-transfer reaction mechanism of cisplatin, can 
be used to decrease the required doses of cisplatin used in the clinic (to effectively reduce 
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Chapter 1. Introduction 
 
Although the use of chemotherapeutic drugs to treatcancers is so vast, patients still suffer 
from extremely poor prognosis. Chemotherapy is especially used for advanced cancer 
patients and is also often combined with radiotherapy or surgery. Ironically, many 
patients die from the toxicities of the drug(s) even b fore the cancers completely take 
over their bodies. To try to increase their efficaces, chemotherapeutic drugs are often 
combined in regimens that allow the drugs to be administered at lower doses, but at the 
expense of spreading the toxicities to several sites of the body [1,2,3]. Even though many 
research groups have tried to form combinational chemotherapeutic regimens to combat 
extreme drug toxicities, they have been unsuccessful in reaching clinical uses. These 
disappointing results have led us to believe that a new approach to designing 
combinational regimens is severely needed.  
 
Section 1.1: General Cancer Treatment 
The three main modalities of cancer treatment are su gery, radiation therapy and 
chemotherapy. The type of treatment a patient receiv s depends on the location and type 
of the cancer, as well as the physical and emotional well-being of the patient. Surgery is 
used to physically remove as much of the tumor mass as possible. Radiation therapy is 
the use of ionizing radiation to kill cancer cells by damaging their DNA, thus disabling 
the cells from growing and further dividing. Cancer hemotherapy is the use of drugs to 
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kill the cancer cells. In general, surgery and radiotherapy provide localized treatments to 
the tumor, whereas chemotherapy is less specific and is on-localized. It is also quite 
common for a patient to receive a combination of these treatment modalities. For 
example, a patient may receive radiation before or after their surgery either to shrink the 
tumor or to get rid of residual cancer cells, respectiv ly [4].  
 New treatment methods have emerged over the years, including immunotherapy, 
photodynamic therapy and gene therapy. Although these methods are rarely used, 
immense efforts are being put forth to make these methods more clinically relevant and 
effective [4].  
 
Section 1.2: Chemotherapy 
The first anti-cancer agent introduced into clinical tri l was the nitrogen mustard (methyl-
bis[chloroethyl]amine hydrochloride), which was deriv d from the sulfur mustard that 
was used during World War I as an offensive weapon. It was found that at low 
concentrations, the mustard gas could incapacitate the nemies by causing irritation to the 
respiratory tract and the eyes. It was then realized that the mustard gas had strong effects 
on rapidly dividing cells such as the gastrointestinal tract and blood-forming organs. 
Through further research, it was determined in 1935 that the mustard gas could inhibit the 
growth of chemically induced tumors in animals. Unfortunately, it was not known 
whether or not the toxic gas would kill the animal before it killed the tumor. Thus, Alfred 
Gilman and Louise Goodman conducted animal studies to investigate the toxicity and 
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pharmacokinetics of the gas and showed that it could significantly lessen lymphoma in 
mice [1]. The potential impact of chemotherapy to anti-cancer applications was then 
solidified to the scientific community and used in practice.  
Chemotherapeutic agents are administered to patients at moderate to severe 
toxicities. The toxic hazards of chemotherapy are generally tolerated because of the belief 
that the higher the dose given, the more likelihood there is a favourable therapeutic 
response. The major life-threatening toxicities that a patient may exhibit include: 
gastrointestinal, bone marrow, hepatic, renal, cardiovascular, neuromuscular and 
respiratory toxicities. Other toxicities that are non-life-threatening but can affect the 
quality of life include nausea, vomiting and alopecia [1]. 
There are several ways to classify anti-cancer agents as some agents also belong 
to more than one group. The classes of anti-cancer ag nts include [1,2,3]:  
• alkylating agents  
 platinum-based anti-cancer drugs 
 bioreductive alkylators 
 anthracyclines  
 topoisomerase inhibitors 
• antimetabolites 
• tubulin-interactive drugs 
1.2.1: Alkylating Agents 
Alkylating agents are those that interact with DNA, RNA or proteins by forming covalent 
chemical adducts [2]; however, it is commonly believed that DNA is the most important 
target for alkylating agents. Alkylation of these biological molecules may occur when the 
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electrophilic agent reacts covalently with their nucleophilic atoms; for example, amino, 
carboxyl, phosphate and sulfhydryl groups in nucleic acids, proteins, amino acids or 
glutathione. Since the nitrogen atom at the 7-position n guanine is highly nucleophilic, it 
is believed to be the main target for alkylation by nitrogen mustards as well as cisplatin 
[5].  
Alkylation of DNA molecules can have biochemical and cellular consequences 
such as activation of enzymatic DNA repair processes, which can lead to single-strand 
breaks if there is a failed attempt at DNA repair. The two strands of the DNA helix may 
also become cross-linked by covalent reaction of the alkylator with two bases either on 
the same or opposite strands, which correspond to intra- and interstrand cross-linking, 
respectively. Alkylators may also alter the DNA base structures, which can cause 
miscoding during the replication process and lead to genetic mutations. These 
interactions with alkylators can effectively lead to cell death. Alkylating agents may be 
classified further as platinum-based, anthracyclines, bioreductive alkylators, or 
topoisomerase inhibitors [2].  
1.2.1.1: Platinum-Based Drugs 
Platinum-based anti-cancer drugs have been greatly investigated. Other metal-based 
compounds have also been synthesized and tested such a  mercury and gold, but 
platinum-based compounds have shown the greatest success. The first prototype was 
cisplatin, which was discovered by accident in 1965 by Dr. Barnett Rosenberg [6]. 
Rosenberg was interested in the effects of electric fields on the growth of bacteria. His 
experimental setup consisted of two platinum electrodes, in which he assumed were inert, 
a water bath and E.coli. Remarkably, he observed that the growth of E.coli was greatly 
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inhibited. Further analysis and testing confirmed that it was the formation of cisplatin 
from the platinum electrodes that was responsible for this inhibition of growth. 
Fortunately, Rosenberg realized the potential of cisplatin in cancer therapy. Today, 
cisplatin is one of the most widely-used chemotherap utic drugs. Other cisplatin analogs 
have been derived and tested, including carboplatin and oxaliplatin. The trans-isomer, 
transplatin, has also been tested, but has not been found to be therapeutically effective 
[1,2,3]. Cisplatin will be discussed in more detail in Section 1.4. 
1.2.1.2: Anthracyclines 
The mechanism of action of anthracyclines on cancer cells is controversial. The 
compounds may: 1) intercalate into DNA to inhibit the synthesis of macromolecules,  
2) form oxidative free radicals that can damage DNA or be involved in lipid 
peroxidation, 3) bind and alkylate the DNA, 4) cross-link with the DNA, 5) interfere with 
the DNA unwinding or DNA strand separation and helicase activity, 6) affect the lipid 
membrane, 7) inhibit topoisomerase II activity to damage DNA and 8) induce apoptosis 
in response to topoisomerase II inhibition [7]. These compounds appear to be more toxic 
to cycling cells than resting cells [1,2,3]. The most common anthracyclines are 
daunorubicin, doxorubicin (marketed as Adriamycin) a d epirubicin. 
1.2.1.3: Topoisomerase II Inhibitors 
Topoisomerase I and II are enzymes that break and rejoin one or both strands of DNA 
molecules, respectively. It is thought that topoisomerase II is the more important 
biochemical target compared to topoisomerase I. Topois merase II is able to form a 
temporary gate through both strands of DNA molecules so that one double-strand DNA 
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segment can pass through another. Topoisomerase II inhibitors bind to and trap the 
covalent complex formed between DNA and the topoisomerase. This effectively causes 
the formation of protein-associated single- or double-strand DNA breaks. Interestingly, 
free radicals can also be formed, which can damage DNA and other macromolecules. 
These complexes also block other important processes like DNA replication, which can 
lead to cell death [2]. Some anthracyclines such as doxorubicin are also considered to be 
topoisomerase II inhibitors. Other topoisomerase inhibitors include camptothecin and 
etoposide [1,2,3]. 
1.2.1.4: Bioreductive Agents 
One main characteristic of tumor cells is their hypoxic environment (lacking oxygen). In 
the early 1950s, Gray et al. exploited the fact that hypoxia reduces the effectiveness of 
radiation treatments [8,9]. In fact, tumor cells with low oxygen levels are up to three 
times more resistant to radiation than those containing oxygen. In the early 1970s, 
Sartorelli et al. proposed the use of a prodrug to target the tumor cells in the hypoxic 
environment [10]. The prodrug can be made so that i is metabolized to a cytotoxic 
compound only in hypoxic cells; otherwise, it would be inactive and would not cause any 
or very little systemic toxicity. 
Bioreductive drugs may also enhance the effects of radiation and standard 
chemotherapeutic drugs since bioreductive drugs are predominantly specific to hypoxic 
cells and radiation and chemotherapeutic drugs are mor  effective at killing aerobic cells. 
In order for bioreductive drugs to be effective, the umor needs to be hypoxic and there 
needs to be an enzyme(s) that is able to reduce the drug to its cytotoxic counterpart [8]. 
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The leading bioreductive agent is tirapazamine (TPZ, 3-amino-1,2,4-benzotriazine 
1,4-dioxide), a heteroaromatic n-oxide compound [11]. Not only does it exhibit excellent 
hypoxia-selective cytotoxicities, but it has been shown that it can greatly enhance the 
efficacies of radiotherapy as well in combination with various chemotherapeutic agents i  
vivo, including cisplatin, cyclophosphamide, etoposide, bl omycin, doxorubicin, 
carboplatin, paclitaxel and 5-FU [12]. Its cytotoxic action is attributed to the one-electron 
reduction by cytochrome P450, P450R and nitric oxide synthase [13,14], generating a 
nitroxide radical intermediate. In the presence of oxygen, the intermediate back-oxidizes 
to the non-cytotoxic parent compound. In the absence of oxygen, the loss of water causes 
the radical intermediate to form an oxidizing radicl that is able to cause DNA damage 
through hydrogen abstraction [15]. TPZ does not exhibit any bystander effects since the 
one-electron product is short-lived. Unlike other bioreductive agents, TPZ also has 
cytotoxicities at intermediate oxygen levels; in other words, TPZ is also able to target 
cells that are radioresistant but are not quite hypoxic for other bioreductive drugs to act 
upon [16]. Since the cytotoxic radical is short-lived, this broadened oxygen selectivity 
can be beneficial. On the contrary, the reduction of TPZ to its cytotoxic radical at 
intermediate oxygen tensions could prevent it from being delivered to chronically 
hypoxic tumor cells [17]. Thus, others have suggested that TPZ analogues be derived 
with improved diffusion characteristics [18,19,20].  
1.2.2: Antimetabolites 
Antimetabolites mimic metabolites that are important in the functioning of the 
biosynthesis of nucleic acids. Because they are chemically similar to endogenous 
metabolites, they use similar cellular uptake mechanisms and metabolic pathways, but 
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due to small differences in their structures, antime abolites can disrupt nucleic acid 
synthesis. Key enzymes may be inhibited or cellular function may be altered after the 
antimetabolites are incorporated into RNA or DNA. Typically, antimetabolites affect 
cells in the S phase of the cell cycle since they disrupt nucleic acid synthesis. The most 
common antimetabolite, 5-Fluorouracil (5-FU), is a fluoropyrimidine antimetabolite that 
metabolically activates to fluorodeoxyuridine monoph sphate (FdUMP), which inhibits 
thymidylate synthetase. It is then activated to flurouridine triphosphate (FUTP), which 
is able to incorporate into RNA molecules. Gemcitabine (2’,2’-Difluorodeoxycytidine) is 
also another common antimetabolite. After cellular ptake, the active metabolite 
(gemcitabine triphosphate) inhibits DNA chain elongation, which can lead to DNA 
fragmentation and thus, cell death [21]. 
1.2.3: Tubulin-Interacting Agents 
Tubulin is a protein that polymerizes to form cellular microtubules, which are structural 
units involved in the formation of mitotic spindles during mitosis. Vinca alkaloids such as 
vincristine and vinblastine bind to tubulin, which inhibits microtubule formation and 
effectively prevents the cell from dividing. Although the antitumor effects are primarily 
from the interaction with tubulin, other biochemical effects include the inhibition of RNA 
and DNA synthesis. Taxanes such as paclitaxel (docetaxel) also interact with tubulin 
molecules, but unlike the vinca alkaloids, paclitaxel overstabilizes the microtubules 
instead of inhibiting their assembly [2,22]. It has al o been reported that paclitaxel can 
cause cell cycle arrest in the G2/M phase [22].  
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Section 1.3: Combinational Chemotherapy  
One method to limit the lethal toxicity of anti-cancer drugs while maintaining the highest 
therapeutic effect is by giving drugs in combination. Although the toxic effects are spread 
amongst different organs and there is a wider range of side effects, the lethal effects are 
minimized. One objective of administering drugs in combination is that the combined 
effect of the drugs is synergistic (greater than additive). The widely-accepted criteria used 
to design combinational drug regimens is the following [1,2,3]:  
• Each drug should be active when used alone  
• Drugs should have different mechanisms of antitumor action 
• The toxic side effects of the drugs should not overlap so that each drug can be 
given at or near their maximum tolerated dose 
• Drugs should have different resistance profiles 
• Drugs may target different cell cycle phases 
As will be shown in this work, this criterion is not necessary to form an effective drug 
regimen. In fact, this criterion should not be followed if one desires to design a regimen 
where one drug can synergistically potentiate the action of another. Even up until now, 
drug regimens are being designed using this criterion – this may be one main reason why 
many combinations have failed and even those that are clinically used do not produce 
satisfactory clinical outcomes. 
There are many combinational therapy regimens availble, depending on the type 
of cancer being treated, as well as the stage of the cancer. Typically, it requires many 
years for a certain regimen to become a gold standard for a specific type of cancer since 
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many clinical trials must be conducted to determine what the side effects are as well as 
the safe levels of dosages.  
Combinational chemotherapy has been found to be far more superior than single-
agent therapy in many types of cancer; for example, the response rates and overall 
survival rates of breast cancer patients have been greatly improved. The prognosis of 
these patients has been greatly increased with the introduction of anthracycline-based 
chemotherapeutic combinations [23]. A well-established regimen is FEC (5-FU + 
epirubicin + cyclophosphamide), which is commonly used to treat patients with both 
early- and late-stage breast cancer [23,24,25]. The FEC regimen has produced response 
rates of approximately 50% [23], with epirubicin being considered as the main 
contributor to the cytotoxic treatment of metastatic breast cancer. The FAC (5-FU + 
doxorubicin + cyclophosphamide) regimen is also commonly used to treat breast cancer 
patients since epirubicin and doxorubicin are structural analogs [23]. The FAC regimen 
also produced some efficacy (response rate of 35%) in the treatment of advanced 
pancreatic cancer, although the responses were short-lived and often not complete [26]. 
 In hopes of finding a combination regimen that would be more effective than the 
FEC combination but without any additional toxicities, the gemcitabine, epirubicin and 
paclitaxel (GET) regimen was tested on patients with metastatic breast cancer [23,27]. 
This combination was formed from previous phase II studies that showed gemcitabine 
having high efficacy towards metastatic breast cancer patients [28]. A phase II study of 
the GET regimen showed promising results (response rates of 92%) [29]. On the 
contrary, a multicenter phase III study conducted by the Central European Cooperative 
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Oncology Group showed that the GET regimen is not superior to the FEC regimen in 
metastatic breast cancer patients [23].  
5-FU is also used in combination with doxorubicin for patients with advanced 
pancreatic cancer [26,30]; however, there is no significant improvement in the survival of 
the patients and many patients experience greater toxic side effects [30]. These findings 
are similar for metastatic pancreatic cancer patients treated with 5-FU, doxorubicin and 
cisplatin. A phase II clinical trial done in 1991 observed a response rate of only 15% for 
non-pretreated patients, which was also accompanied by severe gastrointestinal toxicities 
[26].  
 
Section 1.4: Cisplatin 
Since its approval by the FDA in 1978, cis-diamminedichloroplatinum (II) (also known 
as cisplatinum, cisplatin or CDDP) has become one of the most widely used anti-cancer 
drugs in the world, particularly in testicular, bladder, ovarian and head and neck cancers. 
It is not surprising that most standard combinational chemotherapeutic regimens contain 
CDDP or one of its analogue agents. Despite its wide usage, CDDP suffers from severe 
toxicities and drug resistance (both intrinsic and cquired). Other platinum analogs such 
as carboplatin and oxaliplatin have also been derived to reduce the toxicities of CDDP, 
yet they have not shown such high efficacies as CDDP [1,2,3]. The chemical structure of 






Figure 1.1: Chemical structure of CDDP 
 
Immense efforts have been put forth to gain a deeper understanding of CDDP’s 
mechanism of action. In the intracellular environmet, the Cl-Pt bonds are broken in one 
or two steps, forming cis-Pt(NH3)2 as the end product that can react with DNA, RNA or 
protein molecules to form cross-linked species [1,2,3,31,32,33]. Although CDDP can 
react with various cellular components, DNA is considered to be the therapeutic target. 
These cross-links produce severe distortions in DNA and can lead to unwinding and 
kinking of the DNA strands. Both interstrand as well as intrastrand cross-links can be 
formed, but the majority of the adducts are 1,2-d(GpG) (approximately 65% of adducts) 
and 1,2-d(ApG) (about 25% of adducts) cross-links formed between neighbouring purine 
bases [31,32]. The bending of double-stranded DNA due to the formed 1,2-intrastrand 
cis–[Pt(NH3)2-d(GpG)] cross-link has been shown in solution by nuclear magnetic 
resonance and X-ray crystallography studies [34,35]. 
 
Section 1.5: A New Reaction Mechanism of Action 
Although many postulates have been made about the cy otoxic mechanisms of CDDP, 





with CDDP, the cytotoxic mechanisms need to be understood on a molecular level. The 
most widely-accepted theory is that the chloride atoms are displaced by water molecules 
(aquation), producing the reactive aqua complexes – the majority being [PtCl(H2O)-
(NH3)2]
+ [1,2,3,31,32,33].  
 This widely-accepted hydrolysis reaction of CDDP to form DNA adducts has 
been challenged by Lu et al. [32,33]. Lu reasoned that this hydrolysis reaction is highly 
unlikely to result in the chlorine-bond break when CDDP reacts with DNA. Firstly, since 
the most cytotoxic adduct is attributed to the 1,2-d(GpG) cross-link, a species is required 
to bind to two neighbouring guanine bases. In the hydrolysis of CDDP, it is most likely 
the [Pt(H2O)2-(NH3)2]
2+ that can bind to two neighbouring guanine bases; however, there 
has been evidence that under physiological conditions, this complex is the least likely to 
form [36,37]. Also, the reaction rate constant for the hydrolysis of CDDP has been 
estimated to only be approximately 10-4 M-1s-1 [36]. Furthermore, this was estimated in 
low chlorine concentrations and in the presence of solvents (HClO4 and NaClO4) at 45
oC; 
therefore, this reaction rate constant is even lower under physiological conditions (at 
37oC in an environment containing mostly water).  
It is long known that halogen-containing molecules have extremely efficient 
dissociative attachment reactions with low-energy electrons [38-41]. This reaction can 
produce a halogen anion and a neutral radical. Interestingly, Lu and Madey [42] 
discovered that these electron-induced reactions are largely enhanced by the presence of 
NH3-containing molecules. The dissociative electron tra sfer mechanism proposed by Lu 
and Madey [42] and Lu and Sanche [43] is the following: 
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e-:(NH3)n + ABClx  [ABClx]*
-  Cl- + ABClx-1˙ 
 
where ABClx is a chlorine-containing molecule and e
-:(NH3)n is a presolvated electron 
that is localized in the small polar molecular cluster. From this dissociative electron 
transfer mechanism, Lu predicted that CDDP can have very efficient dissociative 
attachment reactions with weakly-bound electrons because it is a small molecule that 
contains both NH3 and chlorine groups. 
 Using time-resolved pump-probe femtosecond laser sp ctroscopy, Lu and co-
workers discovered the high reactivity of CDDP with weakly-bound prehydrated 
electrons (precursor of the solvated electron) generated in radiotherapy [33], as well as 
the preferential electron transfer reaction of CDDP with the guanine base [32]. In the first 
case, weakly-bound electrons were generated by two-UV-photon excitation of water 
molecules. The following electron transfer reaction between the prehydrated electrons 
and CDDP was monitored: 
 
ep
- + Pt(NH3)2Cl2  [Pt(NH3)2Cl2]*
-  Pt(NH3)2Cl˙ + Cl
- 
ep
- + Pt(NH3)2Cl  [Pt(NH3)2Cl]*
-  Pt(NH3)2˙ + Cl
- 
 
In the second case, Lu et al. demonstrated that in chemotherapy, CDDP preferentially 
reacts with guanine bases by capturing two electrons from two neighbouring guanine 
bases [32].  This is reasonable, since guanine is the most thermodynamically favoured 
electron donor compared to the other three DNA bases. Thus, it was determined that the 
release of chlorine atoms and the binding of Pt(NH3)2 to DNA is due to the electron 
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transfer reaction between the intact CDDP and the guanine bases, which is enhanced by 
the NH3 groups. Interestingly, Lu also observed the strong electron transfer reaction 
between ground-state CDDP and a weakly-bound electron donor [33]. Furthermore, 
enhanced DNA damage was observed when a tiny electron source was produced in 
DNA-CDDP solution [33]. These femtosecond time-resolved laser spectroscopic studies 
provide a deep understanding of the molecular mechanisms of action of CDDP used in 
chemotherapy and in combination with radiotherapy or another chemical agent. 
 
Section 1.6: Combinational Chemotherapy with 
Cisplatin 
Due to its high efficacy in single-agent chemotherapy, it is not uncommon to have a 
patient treated with a CDDP-containing combinational chemotherapeutic regimen. For 
example, a phase III randomized trial published in 1992 [44] compared CDDP and 5-FU 
as single agents and in combination for advanced squamous cell carcinoma of the head 
and neck. The overall response rate of the CDDP and 5-FU combination was 32%, 
whereas those for CDDP or 5-FU alone were 17% and 13%, respectively. Unfortunately, 
patients treated with the combination experienced higher toxicities. Thus, although the 
response rate was higher for the combination compared to the single agents, the survival 
rates did not improve. 
Several groups have demonstrated the anti-cancer activity of paclitaxel given 
alone against ovarian carcinoma, breast carcinoma, lung carcinoma, melanoma and head 
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and neck cancer [45,46]. Due to paclitaxel’s broad activity with different human cancers, 
especially CDDP-sensitive tumors, the paclitaxel and CDDP combination has become 
one of the most commonly used paclitaxel-based chemotherapeutic regimens for solid 
tumors [46]. In preclinical studies, this combination has even shown synergistic 
interactions in a schedule-dependent manner [22,47,48]. Jekunen et al. [48] showed the 
schedule-dependent synergistic interaction of paclitaxel with CDDP in human ovarian 
carcinoma 2008 cells in vitro. Interestingly, this combination was highly synergistic for 
cells treated with paclitaxel first, and then CDDP; however, when this sequence was 
reversed, they observed an antagonistic interaction. These in vitro observations suggest 
the clinical efficacy of this drug combination, but they were unable to identify the 
mechanism responsible for the synergistic interaction between CDDP and paclitaxel. 
Vanhoefer et al. [22] also made similar observations for human gastric and ovarian 
carcinoma cell lines, where the combination was found to be either additive or synergistic 
when paclitaxel was given before CDDP. The antagonistic effects observed for the 
reversed sequence was attributed to the CDDP-induced cell cycle effects since paclitaxel 
also affects the cell cycle (causes a G2/M-interphase blockade), or CDDP-induced 
alterations in the specific or non-specific binding sites of paclitaxel (tubulin).  
Clinical studies have shown conflicting results for the paclitaxel-CDDP 
combination. For example, a phase II study of women with clinically CDDP-resistant 
ovarian cancer who were treated with only paclitaxel only had a response rate of 37% 
[49]. Strikingly, a study done in 1996 by McGuire et al. then showed that the CDDP-
paclitaxel combination can induce a response rate of 73% in advanced ovarian carcinoma 
patients [50]. A phase II trial in 2000 [51] showed activity in patients with advanced 
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esophagus carcinoma who were treated with paclitaxe and CDDP; however, the group 
was not able to recommend the combination tested du to severe toxicities induced on 
patients. Fifty percent of patients were hospitalized for toxicity and 11% died from 
therapy-related complications. Thus, the therapeutic eff cacy of the paclitaxel-CDDP 
combination is dependent on the cancer-type [50,51]. 
As a single agent, gemcitabine has been shown to have activity against metastatic 
non-small-cell lung cancer, ovarian carcinoma, cervi al cancer and head and neck 
squamous cell carcinoma [52-54]. These tumors are also commonly treated with CDDP.  
Due to their differences in toxicity profiles and their predicted mechanisms of action, the 
gemcitabine-CDDP combination has been suggested [53,54]. Thus, this 
chemotherapeutic regimen is one of the most widely-used in clinic in different types of 
cancers including bladder cancer, relapsed breast cancer and pancreatic cancer [30]. Both 
in vitro and in vivo data have suggested that gemcitabine in combination with CDDP can 
provide synergistic interactions if given at the appropriate schedule [21,52,53,54]. This 
synergistic action may be attributed to gemcitabine’s ability to inhibit the removal of 
CDDP-induced DNA interstrand cross-links [21,56]. Using Chinese hamster ovary cell 
lines deficient in the different DNA repair pathways (base excision repair, nucleotide 
excision repair, homologous recombination and non-hmologous end joining), Crul et al. 
[54] suggested that this synergistic interaction betwe n the two drugs may be related to 
homologous recombination of damaged DNA.  
In a phase II study in 2002 [21], patients exhibiting metastatic or recurrent 
nasopharyngeal carcinoma were treated with gemcitabine and CDDP. The gemcitabine-
CDDP combination regimen achieved a high response rate of 78%, where 22% of 
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patients had complete responses, despite half of the patients being previously treated with 
prior chemotherapy or radiotherapy. Patients exhibited only moderate toxicity levels, 
which were considered relatively safe. The gemcitabine-CDDP combination regimen was 
also studied in previously non-treated patients with advanced non-small cell lung cancer 
[52]. The combination induced a high response rate (54%) and produced only modest 
side effects that were only short-lived. 
 Unfortunately, results in a 2008 phase II study were not as promising [57]. The 
clinical activity and toxic tolerability of the gemicitabine-CDDP combination was 
evaluated in chemo-naïve advanced hepatocellular (liver) carcinoma. The trial was 
stopped early due to the lack of efficacy of the drug combination. Progression-free 
survival and overall survival rates were very short; therefore, this group was not able to 
recommend further studies for the gemcitabine-CDDP combination to treat advanced 
hepatocellular cancer patients.  
The bioreductive drug tirapazamine (TPZ) has been shown to enhance the 
response rates in vitro when added to CDDP in certain cell lines. Incubation of cells with 
TPZ and CDDP together under hypoxia increases CDDP-induced DNA interstrand cross-
links, which suggests that TPZ inhibits or delays repair of the DNA cross-links. Although 
this combination is still undergoing clinical trials, the molecular mechanism of the TPZ-
CDDP interaction is still unclear and inconclusive due to inconsistent results from 
various research groups. In fact, Phase III clinical tri ls have been disappointing; TPZ 
was found to introduce additional toxic side effects [19,20]. This is a clear example of the 
use of the classical criterion used to design combinational chemotherapeutic drug 
regimens, where both drugs (TPZ and CDDP) have their own antitumor actions. It is 
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clear that the mechanisms underlying the cytotoxicities of TPZ are still not understood, as 
manifested through the poor outcomes in late clinical trials [16,17,19,20].  
 Although the response rates for CDDP-containing regim ns are relatively high, 
patients still experience extremely high levels of toxicity that are sometimes lethal. In 
fact, some trials have been stopped due to toxic-related deaths [58]. In order to prevent 
lethal events from occurring, in depth studies need to be performed to study the reaction 
mechanisms between drug combinations. 
 
Section 1.7: Motivation and Research Goals 
The work by Lu and co-workers has motivated this combinational chemotherapy study, 
where an electron-donating molecular promoter, namely N, N, N’, N’-Tetramethyl-p-
phenylenediamine (referred to as PM2A in this thesis), is used to enhance the therapeutic 
efficacy of CDDP. PM2A is a well-known biochemical electron donor used in biological 
systems [59]. It is hoped that this modulation by PM2A will result in synergetic effects in 
combination with CDDP. As a result of improved CDDP activities, lower CDDP dosages 
may be used in the clinic; thus, this may greatly reduce the toxic side effects that patients 
experience, effectively improving the prognosis of cancer patients treated with CDDP.  
To test and measure the synergistic effects between PM2A and CDDP, in vitro 
methods were performed on HeLa cells (a cervical cancer cell line) and results presented 
in the following chapters. 
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 The structure of this thesis is organized as the following. This chapter gives an 
introduction on cancer chemotherapy, cisplatin and our research goals. Chapter 2 gives an 
overview of the biological concepts touched upon in th s thesis, including cancer, 
apoptosis and the cell cycle. In Chapter 3, the results of the MTT assay are presented, 
which show the effects of the drug regimen on cell survival rates. Chapter 4 presents 
images using fluorescence microscopy, which are used to visualize the changes in the cell 
morphologies as a result of the PM2A-CDDP combination. In Chapter 5, flow cytometric 
studies are shown to observe the changes in the cell cy le perturbations. Flow cytometry 
is also utilized to show the increase in the amount f fragmented genomic DNA, as 
presented in Chapter 6. In Chapter 7, an absorption spectroscopic study is utilized to 
show the electron-transfer reaction of PM2A with CDDP. Finally, the conclusions are 
given in Chapter 8. 
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Chapter 2. Biological Background 
Section 2.1: Cancer  
Cancer occurs when the cell loses its ability to control and regulate its proliferation, 
differentiation and programmed cell death processes. Mo t cancers will result in the 
development of a solid tumor due to their failure to respond to homeostatic control 
mechanisms [4,78]. 
The cause of cancer lies in the abnormalities of the cell’s genetic material. These 
abnormalities may be caused by carcinogens such as radiation or chemicals. Genetic 
abnormalities may also be inherited from birth, or may occur randomly in processes like 
DNA replication. Even if cellular machinery is unable to repair the genetic abnormalities, 
cancerous cells will still proceed to replicate their erroneous DNA, whereas normal cells 
will undergo programmed cell death (also known as apoptosis) to prevent themselves 
from being replicated [60].  
Hanahan and Weinberg [78] suggested that most human tumors exhibit the 
following physiological characteristics that allow them to become malignant: self-
sufficiency in growth signals, insensitivity to growth-inhibitory signals, evasion of 
programmed cell death, limitless replicative potential, sustained angiogenesis and tissue 





Section 2.2: The Cell Cycle 
The cell goes through the cell cycle in cell proliferation, where its DNA is replicated and 
the replicated chromosomes are segregated, thus dividing the original cell into two 
daughter cells. Cell division consists of interphase, where the cell replicates its DNA, and 
mitosis (M), where the cell physically divides. Interphase is composed of the GAP1 (G1), 
S and GAP2 (G2) phases. The cell first prepares to replicate its DNA in the G1 phase. It 
may choose to go into the dormant G0 phase, where t cell is in a resting state (non-
growing and non-proliferating). After the G1 phase, the cell then starts to replicate its 
DNA in the S phase of the cell cycle. In the G2 phase, RNA and proteins are produced 
and the cell starts to prepare for mitosis [30,61]. The cell cycle is shown in Figure 2.1.   
 









To maintain the integrity of the host organism, apoptosis and cell proliferation 
need to be tightly regulated to eliminate cells that are proliferating abnormally. For this 
reason, apoptosis and proliferation are tightly coupled. Cell cycle checkpoints occur in 
the G1/S phase boundary and also in the G2/M phase boundary [62,63]. These 
checkpoints ensure that cell cycle events occur in o der, and also that critical events 
within a particular phase are completed before the cell proceeds to the next cell cycle 
phase; thus, this prevents the formation of genetically abnormal cells. It is believed that 
arrest in the G1 phase prevents the replication of damaged DNA and arrest in the G2 
phase prevents the cell from segregating defective hromosomes [64]. In response to 
stress on the intracellular or extracellular environments, such as genotoxic stress, the cell 
may arrest at a cell cycle checkpoint. For example, growth arrest may occur if cell cycle 
regulators detect DNA damage or if the chromosomes ar  misaligned on the mitotic 
spindle. At the cell cycle checkpoint, the cell may attempt to repair the damages. If 
successful, the cell will continue to progress through the cell cycle. But if the damage is 
too severe to be repaired, or if the cell fails to repair the DNA, the cell may undergo 
apoptosis to eliminate itself. However, cell cycle regulators in malignant cells may fail to 
determine which one of these options is suitable; for instance, the cell may not decide to 
undergo apoptosis in response to a cytotoxic drug [62]. Thus, it is desirable to search for 




Section 2.3: Apoptosis  
Apoptosis is a multistep process that is orchestrated by a specific sequence of events. The 
timing of each event depends on the type of cell and also the method of induction. 
Apoptosis is marked by the following order of events after induction: collapse of the 
mitochondrial transmembrane potential, caspase activation, externalization of 
phosphatidylserine in the plasma membrane, severe chromatin condensation (not to be 
confused with condensation during mitosis), DNA fragmentation and loss of plasma 
membrane integrity [60,65].  
Apoptotic cells also exhibit hypersegmentation of nuclear chromatin of irregular 
size. These structures bud off from the cell surface nd form “apoptotic bodies”. The late-
stage DNA fragmentation of apoptotic cells, which leads to the disintegration of the 
nucleus, occurs due to the DNA cleavage at sites between nucleosomes at ~200-bp 
intervals. Fragmented DNA produce exposed 3’-OH ends, and thus can be detected using 
in situ assays such as the terminal deoxynucleotidyl transferase dUTP nick end labeling 
(TUNEL) method [66,67].   
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Chapter 3. Cell Survival Study Using the MTT Assay 
Section 3.1: Introduction 
To test the cytotoxic actions of drugs in vitro, the cell survival fraction is usually 
measured by counting the number of cells that either nclude or exclude a dye. One of the 
most common cell viability and proliferation assays used is the MTT assay developed by 
Mosmann in 1983 [68]. This method allows one to count the number of cells indirectly. It 
involves the conversion of yellow MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) to insoluble purple formazan crystals by metabolically-
active cells (live cells). The reduction of MTT occurs in the mitochondria of living cells, 
where the mitochondrial reductase enzymes are active. Using a solubilizing agent, the 
formazan crystals are dissolved and their absorbance measured, giving indication to the 
number of cells that survived. This is a quantitative method that is rapid in terms of the 
required drug treatment time as well as the total protocol time compared to the 
clonogenic assay, which measures cell survival on the long-term scale [69]. Typically, 
the MTT assay can be performed within several days, whereas the clonogenic assay can 
last 1-3 weeks. The clonogenic assay measures the ability of a single cell to grow into a 
colony (one colony is at least 50 cells) and is often used to study cells that are treated 
with ionizing radiation. 
To evaluate the synergistic effects of PM2A in combination with CDDP on cell 
viability, the MTT assay was utilized.  
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Section 3.2: Materials and Methods 
3.2.1: Cell culture and treatment 
HeLa (cervical cancer cell line) cells were purchased from American Type Culture 
Collection. The medium for cell culture was minimum essential medium (MEM) with 
phenol red, which was supplemented with 10% fetal bovine serum (FBS), 100 units/mL 
penicillin G and 100 µg/mL streptomycin. CDDP (Sigma) was dissolved in ultrapure 
water and PM2A in pure ethanol, where the final concentration of ethanol was always 
less than 1% when treated to cells. Ultrapure water with a resistivity of >18.2 MΩ/cm 
was obtained using a NANOpure DIamond TOC Life Scien e ultrapure water system 
(Barnstead International). The cells were split every 3 days, or once they reached a 
confluency of ~85% in 25 cm2 flasks. The cells were cultivated by first rinsing the cells 
twice with phosphate buffered saline (PBS), then trypsinizing for ~2-3 minutes and 
deactivating the trypsin by adding 2 mL of fresh medium. The cells were removed from 
the flask surface by gently washing with medium. The solution was then centrifuged at 
100 g for 5 minutes using an Allegra X-22R Centrifuge (Beckman Coulter). The old 
medium was removed without disrupting the cell pellets, and then 1 mL of new medium 
was added to resuspend the cells by gently pipetting up and down. Approximately 20% of 
the solution containing the cells was then used to further cultivate the cells in 25 cm2 
flasks. Cells were always incubated at 37oC and the CO2 levels maintained at 5% in a 
Forma Series II Water Jacketed CO2 Incubator (Thermo Electron Corporation).  
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3.2.2: Cell survival measurement by MTT 
Cells were seeded in clear 96-well plates (5 x 103 cells/well) in triplicate for 24 h. The 
culture medium containing phenol red (200 µL/well) was replaced by new culture 
medium (200 µL/well) and treated for 24 h with varying drug conce trations in the CO2 
incubator (37oC, 5% CO2). After the drug treatment, cells were replaced with new 
medium (100 µL/well) containing 1.2 mM MTT in phosphate buffered saline (Sigma) 
and incubated for 4 h in the dark in the CO2 incubator. The medium was then removed by 
inverting the microplate on paper towels and gently absorbing the medium. After 
removing any excess medium (containing phenol red), the formazan crystals were 
solubilized with 100 µL DMSO. After 10 minutes of shaking, the fraction of live cells 
was determined by measuring the absorbance at 540 nm using a UV/Vis Multiskan 
absorbance microplate reader (Thermo Scientific), which is directly proportional to the 
number of viable cells. The cell survival rates were calculated by dividing the absorbance 
values of the treated cells by the absorbance of the untreated control cells and multiplying 
by 100 to obtain the percentages. The cell survival rates were plotted against drug 
concentrations to obtain a dose-response plot. 
 
Section 3.3: Results and Discussion 
HeLa cells were treated with 0, 10, 20, 30, 40 and 50 µM CDDP with and without 100 
µM PM2A for 24 h. As shown in Figure 3.1, 100 µM of PM2A provides the maximum 
dose having minimal cell-killing effects as a single agent. Figure 3.2 indicates that a 24 h 
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treatment with CDDP decreases the cell viability in a dose-dependent manner. Treatment 
with only 100 µM PM2A slightly decreases the cell viability compared to the untreated 
cells (85% cell survival rate compared to untreated control). Strikingly, the addition of 
100 µM PM2A to CDDP greatly enhances the effects of CDDP in a synergistic manner, 
which is most prominent for concentrations greater than 20 µM CDDP. At 10 µM of 
CDDP, the cell survival rate decreased from 79% to 64% with the addition of 100 µM 
PM2A. At 20 µM CDDP, the cell survival rate decreased from 72% to 43% with the 
addition of 100 µM PM2A. At concentrations greater than 30 µM CDDP, the addition of 
PM2A killed most or all of the cells, where the absorbance is due to background residual 
formazan. For cells treated with 30 µM CDDP, the addition of 100 µM PM2A resulted in 
a decrease in cell survival rate from 58% to 16%. At 40 µM CDDP, the cell survival rate 
decreased from 44% to 11% with the addition of PM2A. Finally, a treatment of 50 µM 
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Figure 3.2: Cell survival rates for HeLa cells treated with 0 – 50 µM CDDP (+ 100 µM 
PM2A) for 24 h. 
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Section 3.4: Conclusions 
Although the cell-killing effects are not as obvious at lower concentrations of CDDP, it is 
predicted that these effects would be more prominent if the cells were treated for longer 
periods of time. It is possible that the cytotoxic effects of the combination regimen would 
be more obviously manifested at lower CDDP concentrations using an assay that probes 
long-term cell survival, such as the clonogenic assay. Differences in the cell survival 
rates between the single-agent therapy and combinational therapy might have been 
greater at larger CDDP concentrations (greater than 20 µM CDDP). This is likely due to 
the reason that to make the combination therapy effective, certain concentrations of both 
CDDP and PM2A must be present inside the cell or more effectively in the cell nucleus.    
These MTT results suggest that although PM2A, alone, has minimal detrimental 
effects on HeLa cells, the cell-killing effects are significantly increased when the 
combination of PM2A + CDDP is used. This indicates that the effects are synergistic 
since the effects of the combination are greater than e sum of the single-agent effects, 




Chapter 4. Changes in Cell Morphology Using 
Fluorescence Microscopy 
 
Section 4.1: Introduction 
Many chemotherapeutic agents exert their cytotoxic effects by inducing programmed cell 
death, also known as apoptosis. The importance of apoptosis in the cell-killing actions of 
many drugs in vitro has been implicated, including etoposide, camptothecin, vincristine, 
paclitaxel, 5-FU and CDDP [70]. It has also been suggested that the disruption in the 
apoptotic response to CDDP can lead to resistance to CDDP [71]. Thus, it is reasonable 
to conclude that apoptosis is an imperative event in the cytotoxic effects of CDDP on 
cancer cells.  
A landmark apoptotic event is the hypersegmentation of nuclear chromatin of 
irregular size. Apoptotic cells exhibit cell blebbing, resulting in the budding off of these 
structures from the cell surface; these are termed, “apoptotic bodies” [66,67]. This change 
in cell morphology can be observed using a nuclear stain and viewed using fluorescence 







Section 4.2: Materials and Methods 
4.2.1: Cell culture and treatment 
HeLa (cervical cancer cell line) cells were purchased from American Type Culture 
Collection. The medium for cell culture was minimum essential medium (MEM) with 
phenol red, which was supplemented with 10% fetal bovine serum (FBS), 100 units/mL 
penicillin G and 100 µg/mL streptomycin. CDDP (Sigma) was dissolved in ultrapure 
water and PM2A in pure ethanol, where the final concentration of ethanol was always 
less than 1% when treated to cells. Ultrapure water with a resistivity of >18.2 MΩ/cm 
was obtained using a NANOpure DIamond TOC Life Scien e ultrapure water system 
(Barnstead International). The cells were split every 3 days, or once they reached a 
confluency of ~85% in 25 cm2 flasks. The cells were cultivated by first rinsing the cells 
twice with phosphate buffered saline (PBS), then trypsinizing for ~2-3 minutes and 
deactivating the trypsin by adding 2 mL of fresh medium. The cells were removed from 
the flask surface by gently washing with medium. The solution was then centrifuged at 
100 g for 5 minutes using an Allegra X-22R Centrifuge (Beckman Coulter). The old 
medium was removed without disrupting the cell pellets, and then 1 mL of new medium 
was added to resuspend the cells by gently pipetting up and down. Approximately 20% of 
the solution containing the cells was then used to further cultivate the cells in 25 cm2 
flasks. Cells were always incubated at 37oC and the CO2 levels maintained at 5% in a 
Forma Series II Water Jacketed CO2 Incubator (Thermo Electron Corporation).  
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4.2.2: Cell morphological changes by fluorescence m icroscopy  
Cells were cultured in black 96-well plates (~5 x 103 cells/well) for 24 h. The culture 
medium (200 µL/well) was replaced by new culture medium (200 µL/well) and incubated 
in the CO2 incubator (37
oC, 5% CO2) for 11 h with 0, 15, 30 and 50 µM CDDP (+ 100 
µM PM2A). After the drug treatment, cells were gently washed once with PBS (while 
avoiding washing away floating cells) and stained with Hoechst 33342 for 12 minutes. 
The stain was removed and washed once with PBS, then the cells were fixed with 1% 
paraformaldehyde in methanol for 10 minutes and viewed under fluorescence using an 
Eclipse TS100 inverted microscope (Nikon Canada Inc.) and appropriate UV filters. 
Images were taken with a DS-Qi1Mc cooled digital camera (Nikon Canada Inc.).  
 
Section 4.3: Results and Discussion 
Representative fluorescent images of cells treated with different CDDP concentrations 
(with and without the addition of PM2A) for 11 h are shown in Figure 4.1(a-h). Figures 
4.1 a) and b) show untreated cells (0 µM CDDP) and those treated with only 100 µM 
PM2A, respectively. Untreated HeLa cells had intact nuclei and did not exhibit 
condensation of nuclear material. The addition of 100µM PM2A to untreated HeLa cells 
did not change the cell morphology. Cells treated with 15 µM CDDP without and with 
100 µM PM2A (Figure 4.1 c) and d)) had only slight differences in cell morphology. In 
the cells treated with PM2A, we started to observe the formation of DNA condensation 
and apoptotic bodies, as seen by the bright spots in d) and indicated by the red arrows. 
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Cells treated with only 30 µM CDDP exhibited some apoptotic bodies at 11 h of drug 
treatment time (Figure 4.1 e)). With the addition of 100 µM PM2A (Figure 4.1 f)), there 
was some increase in the number of dead cells as indicated by the apoptotic bodies. A 
considerable amount of cells died when treated with50 µM of CDDP for 11 h (Figure 4.1 
g)). But with the addition of 100 µM PM2A, the number of dead cells and apoptotic 
bodies markedly increased, as seen in Figure 4.1 h). It is also interesting to note that there 
were actually more dead cells in the 50 µM CDDP + 100 µM PM2A group that are not 
visible in the image, but were washed away during the staining procedure, as made 











Figure 4.1: HeLa cells treated for 11 h and nuclear-stained with Hoechst 33342. a) 0 µM 
CDDP, b) 0 µM CDDP + 100 µM PM2A, c) 15 µM CDDP, d) 15 µM CDDP + 100 µM 
PM2A, e) 30 µM CDDP, f) 30 µM CDDP + 100 µM PM2A, g) 50 µM CDDP, h) 50 µM 






Section 4.4: Conclusions 
Obvious differences were seen between cells treated with high concentrations of only 
CDDP and CDDP + 100 µM PM2A. These differences were not very significant for cells 
treated with lower concentrations of CDDP (those that are clinically relevant) at 11 h, but 
it is expected that large differences for the lower concentrations would be observed when 
treated for longer periods of time. 
 The cell populations might have contained those that were necrotic (cell injury 
that can cause inflammation; “messy” death), althoug  it was difficult to identify these 
cells by just staining with Hoechst. The cells can be incubated with a cell-impermeable 
stain; necrotic cells would be stained based on the assumption that the plasma membrane 
of necrotic cells are permeable. But the user must be cautious in that the plasma 
membrane of late apoptotic cells also lose their integrity. Therefo, an optimum time-
window to detect this would be early in the apoptotic phase, such that markers like 
caspases are activated. 
  Thus, the efficacy of the PM2A-CDDP combination is supported by the 











Chapter 5. Cell Cycle Analysis by Flow Cytometry 
Section 5.1: Introduction 
It is commonly believed that exposure of cells to CDDP can cause inhibition of DNA 
synthesis and therefore, signal the cell to undergo cell death [31,34]. It has also been 
proposed that CDDP exhibits its cytotoxic effects by triggering G2 cell cycle arrest and 
apoptosis [31,72,73]. At cell cycle checkpoints, DNA lesions may be “sensed”; failure to 
overcome this blockage can lead to cell death [79]. The cytotoxicity of CDDP appears to 
be cell cycle phase independent, but some types of cells may be more sensitive to CDDP 
in the G1 phase [2]. 
To analyze the cell cycle progression and the effects of a drug regimen on the cell 
cycle, one can use flow cytometry to quantify the DNA content. In cell cycle analysis, 
DNA of all cells in the sample are stained by a fluorescent DNA-binding agent such as 
propidium iodide. By noting that cells in the G1 phase have one copy of the DNA and 
two copies in the G2/M phase, the cell population in each phase of the cell cycle can be 
determined. Cells in the S phase exhibit between on and two copies of DNA. If the cells 
are fixed and permeabilized, cells that have fragmented DNA will have less than one 
copy of DNA since the fragmented DNA can escape out of the cells through the porous 
membrane; these are denoted as the sub-G1 fraction and can be attributed to cells that 
have undergone apoptosis. Counting the number of cells having specific amounts of 
DNA would generate a histogram similar to that in Figure 5.1. Cells in the G1 phase 
would exhibit a certain fluorescent intensity, whereas cells in the G2/M phase would have 
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double this intensity. Cells in the S-phase would have intensities between those of G1 and 
G2/M, and cells in the sub-G1 fraction have intensitie  less than that of the G1 fraction 
[74]. For instance, the G1 cells are located at 200 on the DNA Content axis of Figure 5.1, 
G2/M cells at 400, S phase cells in between 200 and 400 and the sub-G1 cells at less than 
200. The broad peaks seen in the histogram depend on the resolution of the flow 
cytometer as well as the levels of variability in the sample population [74]. 
 
 
Figure 5.1: Sample DNA histogram for cell cycle analysis 
 
The cell cycle progression can be analyzed over time o observe where in the 
cycle the cells accumulate. This may provide information on the action of a drug regimen 
and if applicable, which part of the cell cycle thecells are most sensitive to the drug. This 
information is usually cell- and stress-specific. For example, Yamada and Puck observed 
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that low-dose X-irradiation of HeLa cells can lead to a dose-dependent arrest in the G2 
phase [75].  
 
Section 5.2: Materials and Methods 
5.2.1: Cell culture and treatment 
HeLa (cervical cancer cell line) cells were purchased from American Type Culture 
Collection. The medium for cell culture was minimum essential medium (MEM) with 
phenol red, which was supplemented with 10% fetal bovine serum (FBS), 100 units/mL 
penicillin G and 100 µg/mL streptomycin. CDDP (Sigma) was dissolved in ultrapure 
water and PM2A in pure ethanol, where the final concentration of ethanol was always 
less than 1% when treated to cells. Ultrapure water with a resistivity of >18.2 MΩ/cm 
was obtained using a NANOpure DIamond TOC Life Scien e ultrapure water system 
(Barnstead International). The cells were split every 3 days, or once they reached a 
confluency of ~85% in 25 cm2 flasks. The cells were cultivated by first rinsing the cells 
twice with phosphate buffered saline (PBS), then trypsinizing for ~2-3 minutes and 
deactivating the trypsin by adding 2 mL of fresh medium. The cells were removed from 
the flask surface by gently washing with medium. The solution was then centrifuged at 
100 g for 5 minutes using an Allegra X-22R Centrifuge (Beckman Coulter). The old 
medium was removed without disrupting the cell pellets, and then 1 mL of new medium 
was added to resuspend the cells by gently pipetting up and down. Approximately 20% of 
the solution containing the cells was then used to further cultivate the cells in 25 cm2 
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flasks. Cells were always incubated at 37oC and the CO2 levels maintained at 5% in a 
Forma Series II Water Jacketed CO2 Incubator (Thermo Electron Corporation).  
5.2.2: Cell cycle analysis by flow cytometry 
Cells were cultured in clear 6-well plates for 24 h in the CO2 incubator (37
oC, 5% CO2) 
and treated with 0, 5, 10, 15, 25 and 50 µM CDDP (+ 100 µM PM2A) for 12, 24, 48 and 
72 h. Both floating and adherent cells were harvested by trypsinization for ~3 minutes 
and washed twice with PBS by centrifugation (1200 rpm for 8 minutes per cycle). Cells 
were then fixed and permeabilized using 70% ice-cold ethanol for at least 24 h. Before 
staining, cells were pelleted and ethanol was removed by aspiration. Then, each sample 
was washed twice with PBS by centrifugation. Cells were incubated with RNase A (16 
µg/mL) for 30 minutes at 37oC and then stained with propidium iodide (50 µg/mL) for 30 
minutes in the dark. Samples were analyzed using a BD FACSVantage SE flow 
cytometer (Becton, Dickinson and Company) in pulse processing mode (10 000 
cells/sample) and computational analysis performed using FCS Express software (De 
Novo Software, Los Angeles, CA)  to obtain FL2-A DNA content histograms. Data was 
gated on front scatter (FSC) versus side scatter (SSC) to eliminate debris, as well as FL2-
A versus FL2-W to eliminate doublets. Experiments were performed at least 3 times for 






Section 5.3: Results and Discussion 
Figures 5.2, 5.4, 5.6, 5.8, 5.10 and 5.12 show cell cycle histograms for cells treated with 
0, 5, 10, 15, 25 and 50 µM CDDP only and Figures 5.3, 5.5, 5.7, 5.9, 5.11 and 5.13 for 
cells treated with 0, 5, 10, 15, 25 and 50 µM CDDP + 100 µM PM2A. Figures 5.14 – 
5.19 also indicate the percentages of cells in eachcell cycle phase over time for different 
CDDP concentrations.  
Untreated cells exhibited the regular cell cycle distribution as shown in Figure 
5.2. This regular cell cycle distribution was also seen for cells treated with only 100 µM 
PM2A (Figures 5.3 and 5.14). For cells treated with only 5 µM CDDP (Figures 5.4 and 
5.15), the distribution was regular at 12 h, but after 24 h, most of the cells accumulated in 
the S phase. After 48 h, we saw that these cells transitioned past the S-phase and 
accumulated in the G2/M phase. Most of the cells still arrested in the G2/M phase after 
72 h, but some overcame the G2/M checkpoint and transitioned back to the G1 phase. For 
cells treated with 5 µM CDDP + 100 µM PM2A (Figure 5.5), the distribution was regular 
at 12 h, but after 24 h, a larger percentage of cells accumulated in the G1 phase as 
compared to cells treated with only 5 µM CDDP (Figure 5.15). After 48 h, some were 
still arrested at G1, but some also continued to synthesize DNA in the S-phase and also 
reached the G2/M phase. After 72 h, the distribution was very similar to that at 48 h, 
except with a greater percentage of cells in the sub-G1 fraction. Thus, the cells have 
probably arrested and were not able to transition past their checkpoints.  
The cell cycle perturbation pattern for cells treated with 10 µM CDDP only 
(Figures 5.6 and 5.16) was similar to that of 5 µM CDDP + 100 µM PM2A (Figures 5.5 
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and 5.15), where the cells arrested earlier in the cell cycle with the addition of PM2A. A 
12 and 24 h treatment of 10 µM CDDP + 100 µM PM2A (Figure 5.7) did not perturb the 
cell cycle distribution. But after 48 h and 72 h, an increase in the percentages of cells 
accumulating in the early S phase and also in the G1 phase was observed, compared to 
cells treated with only 10 µM CDDP. An increase in the sub-G1 fraction was also 
observed (Figure 5.16).  
 When treated with 15 µM CDDP only (Figures 5.8 and 5.17) for 12 and 24 h, the 
cells had regular cell cycle distributions. After 48 and 72 h, the cells were relatively 
spread throughout the cell cycle phases. But with the addition of 100 µM PM2A (Figures 
5.9 and 5.17), larger percentages of cells accumulated in the G1 phase instead; this is 
more evident with the concomitant decrease in the G2 fraction. The distributions for cells 
treated with 15 µM CDDP for 48 and 72 h were similar to those of 10 µM CDDP + 100 
µM PM2A, except the sub-G1 fractions for the cells trea ed with PM2A were higher. 
 A large proportion of cells treated with 25 µM CDDP only (Figures 5.10 and 
5.18) arrested in the G1 phase, similar to the pattern seen for cells treated with 15 µM 
CDDP + 100 µM PM2A. Interestingly, the sub-G1 fractions were grater for cells treated 
with 15 µM CDDP + 100 µM PM2A compared to cells treated with only 25 µM CDDP. 
The distributions for cells treated with 25 µM CDDP + 100 µM PM2A (Figures 5.11 and 
5.18) were similar to those treated without PM2A where most of the cells accumulated in 
the G1 phase, except the sub-G1 fractions were greater with the addition of PM2A. 
Similar results were also seen for cells treated with 50 µM CDDP with and without 100 
µM PM2A (Figures 5.12, 5.13 and 5.19). 
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Figure 5.2: Cell cycle distributions for 
untreated cells (0 µM CDDP) for 12, 
24, 48 and 72 h. 
Figure 5.3: Cell cycle distributions for 
treated cells (0 µM CDDP + 100 µM 




























Figure 5.4: Cell cycle distributions 
for treated cells (5 µM CDDP) for 12, 
24, 48 and 72 h. 
Figure 5.5: Cell cycle distributions for 
treated cells (5 µM CDDP + 100 µM 





























Figure 5.6: Cell cycle distributions 
for treated cells (10 µM CDDP) for 
12, 24, 48 and 72 h. 
Figure 5.7: Cell cycle distributions for 
treated cells (10 µM CDDP + 100 µM 



























Figure 5.8: Cell cycle distributions 
for treated cells (15 µM CDDP) for 
12, 24, 48 and 72 h. 
Figure 5.9: Cell cycle distributions for 
treated cells (15 µM CDDP + 100 µM 



























Figure 5.10: Cell cycle distributions 
for treated cells (25 µM CDDP) for 
12, 24, 48 and 72 h. 
Figure 5.11: Cell cycle distributions for 
treated cells (25 µM CDDP + 100 µM 

























Figure 5.12: Cell cycle distributions 
for treated cells (50 µM CDDP) for 
12, 24, 48 and 72 h.  
Figure 5.13: Cell cycle distributions for 
treated cells (50 µM CDDP + 100 µM 



































Figure 5.14: Percentages of cells in each phase of the cell cycle for cells treated with  









































Figure 5.15: Percentages of cells in each phase of the cell cycle for cells treated with  
5 µM CDDP (+ 100 µM PM2A) at 12, 24, 48 and 72 h. 
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Figure 5.16: Percentages of cells in each phase of the cell cycle for cells treated with  


































Figure 5.17: Percentages of cells in each phase of the cell cycle for cells treated with  
15 µM CDDP (+ 100 µM PM2A) at 12, 24, 48 and 72 h. 
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Figure 5.18: Percentages of cells in each phase of the cell cycle for cells treated with  
25 µM CDDP (+ 100 µM PM2A) at 12, 24, 48 and 72 h. 
 
 


























Figure 5.19: Percentages of cells in each phase of the cell cycle for cells treated with  
50 µM CDDP (+ 100 µM PM2A) at 12, 24, 48 and 72 h. 
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Section 5.4: Conclusions 
By performing cell cycle analysis for different drug concentrations, we were able to 
observe how the cells transitioned through the cell cyc e phases over time. The 
differences in the cell cycle perturbations were the most obvious for lower concentrations 
of CDDP. For low concentrations of CDDP, it was found that the cells tended to 
accumulate in the G2/M phase, although a great proporti n of cells were able to transition 
past their checkpoints to continue dividing. With the addition of PM2A, large percentages 
of cells were able to accumulate earlier in the cell cycle at the early S phase and even in 
the G1 phase. Compared to cells treated with only CDDP, those treated with the 
combination experienced earlier perturbations in the cell cycle. This may allow the cell’s 
machinery to recognize the effects of CDDP more effctively, possibly due to an 
increased number of CDDP-DNA binding sites and DNA strand breaks. This earlier cell 
cycle arrest may also suggest that the effects of the combinational regimen are much 
more severe compared to the effects of the single agents, thus supporting the efficacy of 




Chapter 6. DNA Fragmentation by Flow Cytometry 
Section 6.1: Introduction 
One late stage marker of apoptosis is the degradation of DNA into small fragments. The 
fragmentation of DNA in apoptotic cells leads to the disintegration of the nucleus, 
occurring between nucleosomes at ~200-bp intervals [66,67]. An enhancement in the 
amount of fragmented DNA can give indication to increases in apoptotic events, and thus 
to the viability of the drug combination. 
Detection of DNA fragmentation can be done using the APO-BrdU TUNEL 
assay, which utilizes the fact that DNA strand breaks expose a large number of 3’-OH 
ends. The hydroxyl groups act as starting points for terminal deoxynucleotidyl transferase 
(TdT) to add deoxyribonucleotides. The break sites ar  labeled by the addition of the 
deoxythymidine analog 5-bromo-2’-deoxyuridine 5’-triphosphate (BrdUTP) in the 
presence of the TdT enzyme. An anti-BrdU antibody conjugated with a fluorescent 
molecule is added to detect the strand breaks by measuring their fluorescence intensities 
using flow cytometry. The cell cycle distribution can also be detected simultaneously 
from the ordinate axis of the generated dot plot (wi h the BrdU-content on the abscissa), 
where the events with fluorescence intensity above the background indicate the cells with 
fragmented DNA (within upper box) [76,77].  The dot plots can also indicate the density 
of the events (number of events per pixel) by the colour, where blue indicates an area 
with high density of events and red indicates a low density.  
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Section 6.2: Materials and Methods 
6.2.1: Cell culture and treatment 
HeLa (cervical cancer cell line) cells were purchased from American Type Culture 
Collection. The medium for cell culture was minimum essential medium (MEM) with 
phenol red, which was supplemented with 10% fetal bovine serum (FBS), 100 units/mL 
penicillin G and 100 µg/mL streptomycin. CDDP (Sigma) was dissolved in ultrapure 
water and PM2A in pure ethanol, where the final concentration of ethanol was always 
less than 1% when treated to cells. Ultrapure water with a resistivity of >18.2 MΩ/cm 
was obtained using a NANOpure DIamond TOC Life Scien e ultrapure water system 
(Barnstead International). The cells were split every 3 days, or once they reached a 
confluency of ~85% in 25 cm2 flasks. The cells were cultivated by first rinsing the cells 
twice with phosphate buffered saline (PBS), then trypsinizing for ~2-3 minutes and 
deactivating the trypsin by adding 2 mL of fresh medium. The cells were removed from 
the flask surface by gently washing with medium. The solution was then centrifuged at 
100 g for 5 minutes using an Allegra X-22R Centrifuge (Beckman Coulter). The old 
medium was removed without disrupting the cell pellets, and then 1 mL of new medium 
was added to resuspend the cells by gently pipetting up and down. Approximately 20% of 
the solution containing the cells was then used to further cultivate the cells in 25 cm2 
flasks. Cells were always incubated at 37oC and the CO2 levels maintained at 5% in a 




6.2.2: DNA fragmentation measurement by flow cytome try  
 
Cells were cultured in 25 cm2 flasks (~8 x 107 cells/flask) for 24 h in the CO2 incubator 
(37oC, 5% CO2). The culture medium (~7 mL per flask) was replaced by new medium 
and incubated for 48 h with varying drug concentrations in the CO2 incubator. Both 
floating and adherent cells were harvested by trypsinization for ~3 minutes, washed twice 
with PBS by centrifugation (300 g for 5 min) and fixed using 1% paraformaldehyde for 
30 min on ice. Cells were then permeabilized by suspending the cells in 70% ice-cold 
ethanol for at least 24 h at -20oC. To label the DNA, ethanol was removed after 
centrifugation and cells were resuspended in 50 µL of TUNEL reaction buffer containing 
terminal deoxynucleotidyl transferase and BrdUTP for 1 h at 37oC in the dark, shaking 
every 15 min. After overnight room temperature incubation in the dark, the cells were 
then incubated with Alexa Fluor 488-conjugated BrdUTP-antibody for 30 min at room 
temperature in the dark. Cells were also subsequently stained with propidium iodide (5 
µg/mL) and incubated with RNase A for 30 min at room te perature to determine the 
total cellular DNA content. Samples were then analyzed using a Becton-Dickinson 
FACSVantage SE flow cytometer in pulse processing mode (10 000 cells per sample). 
Computational analyses were performed using FCS Express software (De Novo 
Software, Los Angeles, CA) to obtain FL1-H versus FL2-A dot plots (log versus linear, 
respectively), gating on front scatter (FSC) versus side scatter (SSC) to eliminate debris, 
as well as FL2-A versus FL2-W to eliminate doublets. Experiments were performed 
independently at least 3 times. 
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Section 6.3: Results and Discussion 
HeLa cells were treated with 0, 10, 25 and 50 µM CDDP with and without 100 µM 
PM2A for 48 h. As shown in Figure 6.1, 1% of untreaed cells exhibited DNA 
fragmentation, which can be attributed to cells naturally undergoing cell death. Most of 
the events were in the G1 phase of the cell cycle, which is characteristic of a regular cell 
cycle distribution. Figure 6.2 shows that 2% of cells treated with only 100 µM PM2A had 
DNA fragmentation. When cells were treated with 10 µM CDDP + 100 µM PM2A, the 
percentages increased from 9% to 18% compared to cells treated with only 10 µM CDDP 
(Figures 6.3 and 6.4). Remarkably, the percentages increased from 6% to 69% when cells 
were treated with 25 µM CDDP without and with 100 µM PM2A, respectively (Figures 
6.5 and 6.6). The percentages also dramatically increased from 38% to 74% when cells 
were treated with 50 µM CDDP, without and with 100 µM PM2A, respectively (Figures 
6.7 and 6.8). Consistent with the cell cycle analysis in Chapter 5, it was observed that 
when CDDP was used as a treatment in combination with PM2A, the cells arrested in the 
early S phase and G1 phase of the cell cycle, whereas the cells tended to accumulate in 
the G2/M phase for lower doses of CDDP as a single a ent. Interestingly, the dot plots 
indicated that more cells will undergo DNA fragmentation when they are accumulated in 
the G1 phase. Although cells in all phases of the cell cycle will undergo cell death (non-
specific), this will occur maximally for cells in the G1 phase. Thus, there is a significant 
increase (synergistic) in DNA fragmentation when PM2A is added in combination with 




Figure 6.1: Results for APO-BrdU DNA Fragmentation Assay for cells treated with 0 
µM CDDP for 48 h. Density plot illustrates BrdU-positive cells as a function of the DNA 
content (position in the cell cycle). The colours indicate the number of events in each 
pixel. Three independent trials were performed and the mean percentage of BrdU-




Figure 6.2: Results for APO-BrdU DNA Fragmentation Assay for cells treated with 0 
µM CDDP + 100 µM PM2A for 48 h. Density plot illustrates BrdU-positive cells as a 
function of the DNA content (position in the cell cycle). The colours indicate the number 
of events in each pixel. Three independent trials were performed and the mean percentage 






Figure 6.3: Results for APO-BrdU DNA Fragmentation Assay for cells treated with 10 
µM CDDP for 48 h. Density plot illustrates BrdU-positive cells as a function of the DNA 
content (position in the cell cycle). The colours indicate the number of events in each 
pixel. Three independent trials were performed and the mean percentage of BrdU-




Figure 6.4: Results for APO-BrdU DNA Fragmentation Assay for cells treated with 10 
µM CDDP + 100 µM PM2A for 48 h. Density plot illustrates BrdU-positive cells as a 
function of the DNA content (position in the cell cycle). The colours indicate the number 
of events in each pixel. Three independent trials were performed and the mean percentage 






Figure 6.5: Results for APO-BrdU DNA Fragmentation Assay for cells treated with 25 
µM CDDP for 48 h. Density plot illustrates BrdU-positive cells as a function of the DNA 
content (position in the cell cycle). The colours indicate the number of events in each 
pixel. Three independent trials were performed and the mean percentage of BrdU-




Figure 6.6: Results for APO-BrdU DNA Fragmentation Assay for cells treated with 25 
µM CDDP + 100 µM PM2A for 48 h. Density plot illustrates BrdU-positive cells as a 
function of the DNA content (position in the cell cycle). The colours indicate the number 
of events in each pixel. Three independent trials were performed and the mean percentage 





Figure 6.7: Results for APO-BrdU DNA Fragmentation Assay for cells treated with 50 
µM CDDP for 48 h. Density plot illustrates BrdU-positive cells as a function of the DNA 
content (position in the cell cycle). The colours indicate the number of events in each 
pixel. Three independent trials were performed and the mean percentage of BrdU-
positive cells calculated. 38% of cells were BrdU-positive. 
 
 
Figure 6.8: Results for APO-BrdU DNA Fragmentation Assay for cells treated with 50 
µM CDDP + 100 µM PM2A for 48 h. Density plot illustrates BrdU-positive cells as a 
function of the DNA content (position in the cell cycle). The colours indicate the number 
of events in each pixel. Three independent trials were performed and the mean percentage 




Section 6.4: Conclusions 
It is interesting to note that the percentages of DNA fragmentation were relatively the 
same for cells treated with 10 µM and 25 µM CDDP, although the 10 µM CDDP 
population mostly arrested at the G2/M phase and the 25 µM CDDP population in the G1 
phase. But with the addition of PM2A to CDDP, the increase in DNA fragmentation 
percentages was significantly greater for 25 µM CDDP than 10 µM CDDP. It is possible 
that at higher CDDP concentrations (such as 25 µM CDDP) of the drug combination, 
necrosis is also induced alongside apoptosis. It is also possible that some proportion of 
cells underwent apoptosis but transitioned to secondary necrosis. This large difference 
between the high and low concentrations of the combination may also be attributed to the 
fact that to make the combinational therapy effective, certain concentrations of both 
CDDP and PM2A must be present inside the cell or more effectively in the cell nucleus. 
The differences between the high and low concentrations of CDDP can be correlated with 
the MTT results presented in Chapter 3. A relatively small increase in the cell survival 
rates were seen when PM2A was added to CDDP concentratio s less than 20 µM, 
whereas significantly large differences were seen for CDDP concentrations greater than 
20 µM.  
 Although PM2A, as a single agent, had minimal effects on DNA fragmentation of 
HeLa cells, it was shown that the addition of this compound to CDDP greatly enhanced 
its DNA fragmentation effects. Furthermore, this synergistic enhancement also 
corresponded to earlier cell cycle arrests in the S and G1 phases, as compared to G2/M 
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arrest for cells treated with only CDDP. This provides evidence as to why and how 
PM2A is able to enhance the efficacy of CDDP on a cellular level.  
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Chapter 7. Absorption Spectroscopic Analysis 
 
Section 7.1: Introduction 
Solvents providing reductive environments such as ethanol may be able to prevent PM2A 
from losing its electron. On the other hand, the tendency for PM2A to donate its electron 
is highly probable in oxidative environments such as w ter with the presence of oxygen; 
thus, PM2A is expected to be quite unstable in aerobic water environments. Furthermore, 
the presence of an electron-accepting molecule (relativ  to PM2A) would result in the 
competition of the electron between this constituen and oxygen. We expect to observe 
this competition of the electron from PM2A between CDDP and oxygen.  
The static absorbance spectra of PM2A under several conditions were obtained to 
determine its reactivity in different solvent environments over time since absorbance 
spectroscopy probes electronic transitions. 
 
Section 7.2: Materials and Methods 
Static UV/Vis absorption spectroscopy was performed for a 100 µM PM2A solution in 
pure ethanol, 100 µM PM2A solution in 1% ethanol and 100 µM PM2A + 50 µM CDDP 
solution in 1% ethanol. 10 mM PM2A stock solutions were prepared in pure ethanol 
immediately before measurements. Cisplatin (Sigma) was dissolved in ultrapure water. 
Ultrapure water with a resistivity of >18.2 MΩ/cm was obtained using a NANOpure 
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DIamond TOC Life Science ultrapure water system (Barnstead International). 
Absorbance readings were scanned from 190 nm to 1000 nm at different time points after 
the initiation of the reaction (through mixing of the solution by inversion) using a DU 
530 Life Science UV/Vis Spectrophotometer (Beckman Coulter). Absorbance 
measurements were made in quartz cuvettes and all experimental steps (including sample 
preparation) were performed in the dark. The baseline for measurements were made with 
pure ethanol for the 100 µM PM2A solution in pure ethanol sample, and made in 
ultrapure water for the 100 µM PM2A solution in 1% ethanol and 100 µM PM2A + 50 
µM CDDP solution in 1% ethanol samples. 
 
Section 7.3: Results and Discussion 
Figure 7.1 shows the absorbance spectrum of 100 µM PM2A in pure ethanol. The 
spectrum was measured at various time points between 0 to 24 h, but it was found that it 
did not change during this time period. Absorbance peaks were observed at 204 nm, 261 



















Figure 7.1: Static absorption spectrum for 100 µM PM2A in pure ethanol. The spectrum 
did not change over the 24 h period. 
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In in vitro experiments, the percentage of the PM2A vehicle was always 1% 
ethanol.  As evident from Figures 7.1 and 7.2, the absorbance spectrum for 100 µM 
PM2A in 1% ethanol at the beginning of the reaction (0 h) was slightly different from 
that in pure ethanol. Peaks were seen at 196 nm, 255 nm, 325 nm, 561 nm and 612 nm. 
The peaks at 196 nm, 255 nm and 325 nm corresponded to peaks at 204 nm, 261 nm and 
314 nm in the 100 µM PM2A in pure ethanol spectrum, but slightly shifted.  
 Absorbance spectra were measured for 100 µM PM2A in 1% ethanol for varying 
points and were found to change over time. The spectra at 0, 2 and 8 h are shown in 
Figure 7.2. Initially, peaks were seen at only 196 nm and 255 nm. Additional peaks at 
325 nm, 561 nm and 612 nm started to form shortly af er the start of the reaction. The 
additional peaks at 561 nm and 612 nm were not seen in the 100 µM PM2A in pure 
ethanol spectrum. The isobestic point occurred at 283 nm; thus, the absorbances at 
wavelengths less than 283 nm decreased over time, and those at wavelengths greater than 
283 nm increased over time. 
 The spectra were also measured for 100 µM PM2A in 1% ethanol with the 
addition of 50 µM CDDP, as shown in Figure 7.3. CDDP only had some absorbance at 
196 nm but did not have absorbance at wavelengths greater than this. At the beginning of 
the measurement (0 h), the spectrum for 100 µM PM2A + 50 µM CDDP in 1% ethanol 
was very similar to that of only 100 µM PM2A in 1% ethanol, having the same peak 
positions. Measurements are shown for 0, 2 and 8 h after the initiation of the reaction. 
The spectra also changed over time, having the sameisob stic point at 283 nm.  
 Since the absorbance spectra changed over time for 100 µM PM2A (+ 50 µM 
CDDP) in 1% ethanol, the absorbance values were plotted as a function of time for each 
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peak wavelength (refer to Figures 7.4-7.8). For all peak wavelengths, the absolute rates of 
change for the absorbances were greater with the addition of CDDP. For peak 
wavelengths 196 nm and 255 nm (wavelengths less than the isobestic point), the 
absorbance values decreased at greater rates for 100 µM PM2A + 50 µM CDDP (Figures 
7.4 and 7.5). On the other hand, the absorbance valu s increased at greater rates for 100 
µM PM2A + 50 µM CDDP (Figures 7.6, 7.7 and 7.8) for peak wavelengths 325 nm, 561 
nm and 612 nm (wavelengths greater than the isobestic point). 

















































Figure 7.3: Static absorption spectrum for 50 µM CDDP + 100 µM PM2A in 1% ethanol 
























100µM PM2A + 50µM CDDP
Figure 7.4: The change in the absorbance spectra over time at th  196 nm peak for 100 


















100µM PM2A + 50µM CDDP
Figure 7.5: The change in the absorbance spectra over time at th  255 nm peak for 100 





























100µM PM2A + 50µM CDDP
Figure 7.6: The change in the absorbance spectra over time at th  325 nm peak for 100 


















100µM PM2A + 50µM CDDP
Figure 7.7: The change in the absorbance spectra over time at th  561 nm peak for 100 




























100µM PM2A + 50µM CDDP
Figure 7.8: The change in the absorbance spectra over time at th  612 nm peak for 100 





Section 7.4: Conclusions 
It was observed that the absorbance spectra for PM2A dissolved in pure ethanol did not 
change over time; thus showing its stability in a reductive environment. The changes in 
the absorbance spectra of 100 µM PM2A in 1% ethanol over time most likely indicated 
the instability of PM2A in an oxidative environment. On the other hand, the changes in 
the absorbance spectra of 100 µM PM2A in 1% ethanol increased with the addition of 




Chapter 8. Conclusions  
In this study, it was shown that one should not simply follow the classical criterion for 
designing combinational chemotherapeutic drug regimns. To reiterate from Section 1.3, 
the criteria are the following [1,2,3]: 
• Each drug should be active when used alone  
• Drugs should have different mechanisms of antitumor action 
• The toxic side effects of the drugs should not overlap so that each drug can be 
given at or near their maximum tolerated dose 
• Drugs should have different resistance profiles 
• Drugs may target different cell cycle phases 
Ideally, if one were to design a drug regimen where on  drug can synergistically 
potentiate the action of another, additional toxic side effects should not be introduced into 
the specimen. The introduction of additional toxic side effects to a wider range of organs 
is a direct consequence of the classical criterion. In order to limit the drug toxicities, it is 
recommended that each drug should not be active when us d alone, they should not have 
different mechanisms of antitumor action, their toxic side effects should overlap and they 
may not need to have different resistance profiles or target different cell cycle phases.  
 The results of this study are direct evidence that a new criterion is urgently needed 
and that the classic criterion should not mechanically followed. The viability of the 
molecular promoter PM2A in enhancing the cytotoxic effects of CDDP in a cervical 
cancer cell line was shown, while introducing minimal additional toxicities. PM2A was 
chosen as the molecular promoter based on the new mechanistic understanding of how 
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CDDP is able to attack DNA [32,33]. It is now understood that the cytotoxic action of 
CDDP can be attributed to its high reactivity with weakly-bound precursor electrons, thus 
being able to preferentially bind to guanine bases and generating DNA-damaging 
radicals. The role of PM2A is to enhance the DNA-damaging effects of CDDP by 
donating its electrons to CDDP to generate more radicals. Thus, the administered doses 
of CDDP may be reduced, while still producing the same or even higher therapeutic 
effects. By reducing the doses of CDDP, its toxic side effects are also halted. 
First, the MTT assay was used to evaluate the effects of the drug combination on 
cell survival rates. Then, fluorescence microscopy was used to visualize the differences in 
the cell morphological changes between the single aents and the combination regimen; 
in particular, it was hoped to observe increases in the number of apoptotic cells in the 
combinational regimen. These methods showed significa t increases in the number of 
dead cells when the cancer cells were treated with bot  PM2A and CDDP. 
Flow cytometry was then used to perform cell cycle analysis, in which cell cycle 
perturbations were observed. While a treatment of low doses of CDDP caused arrest in 
the G2/M phase of the cell cycle, the combination of PM2A + CDDP resulted in 
accumulations earlier in the cell cycle (S phase and even the G1 phase). This also resulted 
in increases in the sub-G1 fraction.  
Flow cytometry was also used to analyze the amount f cells exhibiting increased 
percentages of DNA fragmentation, a landmark of apoptosis. The addition of PM2A to 
CDDP treatment to HeLa cells significantly increased the levels of DNA fragmentation. 
Furthermore, this also corresponded to earlier cell cycle arrest in the G1 phase, giving 
possible implications as to how the cell undergoes apoptosis on a cellular level. 
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Furthermore, the synergistic action of the drug combination should only be 
localized to the tumor site. By taking advantage of the hypoxic environment of tumors, 
the cell-killing effects of CDDP may be enhanced only at tumor sites. In other words, 
PM2A would only be able to lose its electron to CDDP, thus enhance its effects, at the 
tumor site (in hypoxic or reductive environments). On the contrary, PM2A should be 
oxidized by the aerobic environment (oxygen present in water, for example) and be 
limited in donating its electron to CDDP. These criteria are very important in localizing 
the antitumor action and limiting the toxic side effects. This localizability is based on the 
electron-transfer mechanism between PM2A and CDDP. Absorption spectroscopic 
studies showed that the absorption spectra of PM2A are drastically changed by the 
presence of CDDP. This suggests the strong electron-transfer reaction between PM2A 
and CDDP, consistent with the finding that CDDP is a very effective electron acceptor 
and the fact that PM2A is a well-known biological electron donor. The spectra of PM2A 
were very stable over time in a reductive environmet, suggesting that it would be able to 
preferentially react with CDDP in hypoxic environments. The spectra of PM2A were 
unstable over time in an oxidative environment, indicating that a limited amount of 
PM2A would be able to donate its electrons to CDDP, thus greatly reducing the cytotoxic 
action at non-hypoxic sites (non-tumor sites, for example).   
In closing, this work implicates that clinical doses of CDDP can be significantly 
reduced when administered in combination with PM2A, thus minimizing the toxic side 
effects that CDDP-treated patients currently experience, since PM2A alone exhibits 
minimal detrimental effects. Effectively, this would greatly decrease the number of 
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patients who suffer from toxic-related deaths and thus, significantly improve the 
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